Cypress Biosciences (CYPB) is down 74 cents to $7 after the company, along with partner Forest Labs (FRX), said shipping of Savella to wholesalers and pharmacies will begin mid-2009. The treatment, approved in January, was expected to be shipped this month. CYPB options volume is running at 3X the normal, with increasing interest Jan 7.5 calls. Looks like sellers collecting $1, perhaps part of a buy-write strategy.